Table 2.
Overview of clinical studies performed by using FT-IR spectroscopy as a diagnosis tool in vivo in humans.
| Methodology | Disease Type/Metabolite | Patient Number | Results | Reference | ||
|---|---|---|---|---|---|---|
| Sensitivity | Specificity | Accuracy | ||||
| Benchtop ATR | Breast Cancer | 100 | 90 | 98 | 94 | [40] |
| Miscroscope Trans-reflectance | 20 | [41] | ||||
| Benchtop Transmission | 86 | 76 | 72 | 80 | [42] | |
| Benchtop Trans-reflectance | 196 | Cluster analysis: 98 | Cluster analysis: 95 | [43] | ||
| ANN *: 92 | ANN: 100 | |||||
| Microscope | Breast Cancer-ECM3 * gene | 97 | 91 | 95 | [44] | |
| Benchtop ATR–FTIR | Skin Cancer | 7 | [45] | |||
| Benchtop | Cervical Precancer | 100 | 95.2 | 97.4 | [46] | |
| Benchtop | Leukemia | 34 | 83.3 | 79 | [47] | |
| Microscope | 51 | [48] | ||||
| Microscope ATR | Colon Cancer | 78 | 100 | 93.1 | 95.8 | [49] |
| Benchtop ATR | Ovarian Cancer (blood tested) | 30 | 100 | 100 | [50] | |
| Benchtop | Gastric Cancer (serum tested) | 46 | 100 | 80 | [51] | |
| Microscope | Lung Cancer | 99.3 | 94.4 | 96.8 | [52] | |
| Microscope Trans-reflectance | Lung Tumor (tissue tested) | 112 | 97 | [53] | ||
| Benchtop Transmittance | Bladder Cancer | 136 | 100 | 58.8 | [54] | |
| Benchtop Reflectance | 90 | 80.9 | ||||
| Benchtop Transmission | Malignant Biliary Strictures | 57 | 90 | 100 | [55] | |
| Benchtop | Invasive Ductal Carcinoma | 229 | 91.7 | 100 | 95.7 | [56] |
| Benchtop ATR | FM * | 252 | 89.5 | 79 | 84.2 | [57] |
| Microscope ATR | FM, OA *, RA * | 41 | 100(SIMCA *); 75(RF *) | [58] | ||
| Portable ATR | FM, RA, SLE * | 70 | no misclassified sample | [39] | ||
| Benchtop | Burning Mouth Syndrome (saliva tested) | 28 | Area under the ROC curve calculated as 0.75 | [59] | ||
| Microscope | Human Papillomavirus | 50 | 76.9 | 76.7 | [60] | |
* ANN: Artificial Neural Networks, ECM3 gene: Extracellular Matrix Cluster 3, SIMCA: Soft Independent Modeling Class Analogy, RF: Random Forest, FM: Fibromyalgia, OA: Osteoarthritis, RA: Rheumatoid Arthritis, SLE: Systemic Lupus Erythematosus.